Endpoint surrogacy in oncology Phase 3 randomised controlled trials.


Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint-instead of overall survival-would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.





Published Version (Please cite this version)


Publication Info

Zhang, Jianrong, Meagan R Pilar, Xiaofei Wang, Jingxia Liu, Herbert Pang, Ross C Brownson, Graham A Colditz, Wenhua Liang, et al. (2020). Endpoint surrogacy in oncology Phase 3 randomised controlled trials. British journal of cancer, 123(3). pp. 333–334. 10.1038/s41416-020-0896-5 Retrieved from https://hdl.handle.net/10161/30411.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.



Xiaofei Wang

Professor of Biostatistics & Bioinformatics

Design and Analysis of Clinical Trials
Methods for Diagnostic and Predictive Medicine
Survival Analysis
Causal Inference
Analysis of Data from Multiple Sources


Herbert Pang

Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics

Classification and Predictive Models
Design and Analysis of Biomarker Clinical Trials
Pathway Analysis

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.